Amycretin: Peptide Profile, CAS & Properties
CAS 3005889-81-3 · ≈ 7846.58 g/mol
Amycretin (INN zenagamtide; CAS 3005889-81-3) is a 68-amino-acid unimolecular GLP-1 and amylin receptor co-agonist, molecular formula C343H550N94O116. It is investigational, in clinical development for obesity and type 2 diabetes, and not yet approved by any major regulator. This page provides reference information on Amycretin.
- CAS Number
- 3005889-81-3
- Molecular Formula
- C343H550N94O116
- Molecular Weight
- ≈ 7846.58 g/mol
- Drug Class
- GLP-1 / amylin receptor co-agonist
What is Amycretin?
Amycretin (INN zenagamtide; also referenced as NN9487) is a unimolecular GLP-1 and amylin receptor co-agonist — a single 68-amino-acid peptide in which a glucagon-like peptide-1 (GLP-1) receptor-agonist moiety and an amylin receptor-agonist moiety are covalently joined within one molecular entity. This hybrid design engages two complementary appetite- and metabolism-regulating pathways through one molecular entity, and both subcutaneous and oral formulations have been studied in clinical trials.
Chemically, amycretin (CAS 3005889-81-3) has the molecular formula C343H550N94O116 and a molecular weight of approximately 7846.58 g/mol. It is investigational: it is in clinical development for obesity and type 2 diabetes and is not yet approved by the FDA, EMA or other major regulators for any indication.
How Amycretin Is Produced & Characterised
Amycretin is a long, structurally complex peptide: its 68-mer length, the dual-pharmacophore architecture and the internal linker all create opportunities for deletion sequences, diastereomers and incomplete couplings. Peptides of this class are typically produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling and conjugation chemistry, then purified on preparative dynamic axial compression (DAC) HPLC columns to resolve the target sequence from closely related impurities, and lyophilised to a stable powder.
Analytical characterisation of such peptides generally combines UPLC/HPLC for purity determination with LC-MS to confirm the intended sequence and to profile minor structural variants. These approaches are described here as general, industry-standard reference information on how a peptide of this size and complexity is prepared and assessed.
Typical Quality Specifications & Impurity Profiling
For research-grade peptides of this class, a representative specification defines appearance, purity and an impurity profile released against a Certificate of Analysis. Purity is typically determined by UPLC/HPLC, with the sequence and minor structural variants confirmed by LC-MS impurity profiling; high-grade material is commonly specified at ≥99.0% purity, with individual impurities controlled below 0.10%.
Stability behaviour is usually characterised under ICH Q1A(R2) long-term and accelerated conditions, and parameters such as water content, counter-ion content, residual solvents and peptide content are measured. Analytical methods for this purpose are generally validated to ICH Q2(R1). The figures here are typical reference values for the peptide class, not a guaranteed specification for any particular material.
Regulatory & Development Status
Amycretin is an investigational molecule. As of its current development stage it is in clinical trials for obesity and type 2 diabetes and has not been approved by the FDA, EMA or other major regulators for any indication. Investigational peptides of this kind are referenced in clinical-stage submissions through CTD Module 3 CMC sections (for IND/IMPD) and, where applicable, Drug Master File (DMF)-style dossiers, supported by analytical validation packages to ICH Q2(R1) and stability data.
This section is provided as educational context on the regulatory framework surrounding investigational peptide APIs. It does not constitute medical or regulatory advice, and no therapeutic or efficacy claims are made for amycretin.
Amycretin API — Specifications
| CAS Number | 3005889-81-3 |
|---|---|
| Molecular Formula | C343H550N94O116 |
| Molecular Weight | ≈ 7846.58 g/mol |
| Sequence | 68 amino acids, unimolecular GLP-1 / amylin co-agonist |
| Drug Class | GLP-1 / amylin receptor co-agonist |
| Regulatory Status | Investigational; not yet approved |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + DAC prep-HPLC purification |
| Form | Lyophilised powder |
| Storage | Store at -20°C, protected from light & moisture |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Investigational; in clinical development and not yet approved by the US FDA, EMA or other major regulators for any indication.
Amycretin API — Frequently Asked Questions
What is Amycretin?
Amycretin (INN zenagamtide; also referenced as NN9487) is a 68-amino-acid unimolecular GLP-1 and amylin receptor co-agonist — a single peptide combining a GLP-1 receptor-agonist moiety and an amylin receptor-agonist moiety, joined by a short Gly/Glu linker. Both subcutaneous and oral formulations have been studied in clinical trials.
What is the CAS number and molecular weight of Amycretin?
Amycretin's CAS number is 3005889-81-3, its molecular formula is C343H550N94O116, and its molecular weight is approximately 7846.58 g/mol.
Is Amycretin an approved drug?
No. Amycretin (INN zenagamtide) is investigational and in clinical development for obesity and type 2 diabetes. It is not yet approved by the FDA, EMA or other major regulators for any indication.
What class of peptide is Amycretin?
Amycretin is a GLP-1 / amylin receptor co-agonist within the GLP-1 and incretin multi-agonist class. It is unimolecular, meaning both the GLP-1 and amylin receptor-agonist activities are built into a single peptide rather than a combination of separate molecules.
What is Amycretin being studied for?
Amycretin is in clinical development for obesity and type 2 diabetes. Its dual GLP-1 and amylin receptor agonism is intended to engage two complementary appetite- and metabolism-regulating pathways through one molecular entity.
How is a peptide like Amycretin typically produced?
Peptides of this class are generally made by Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling and conjugation chemistry, followed by preparative dynamic axial compression (DAC) HPLC purification and lyophilisation to a stable powder. Purity is typically assessed by UPLC/HPLC and the sequence confirmed by LC-MS. This is general reference information about the peptide class.
Related Peptide APIs
Cagrilintide API
CAS 1415456-99-3
GLP-1 & Incretin Multi-AgonistsRetatrutide API
CAS 2381089-83-2
GLP-1 & Incretin Multi-AgonistsSemaglutide API
CAS 910463-68-2
GLP-1 & Incretin Multi-AgonistsTirzepatide API
CAS 2023788-19-2
Technical Reference Page
WinHyCare neither supplies nor manufactures Amycretin; this page is provided as a technical reference. The peptide API we supply is Semaglutide.